Key Disease Characteristics Influencing the Choice Between ICI + TKI and ICI + ICI Regimens in mRCC
Panelists discuss how specific disease characteristics, such as tumor burden, metastatic sites, and risk stratification, most strongly influence their decision-making process when choosing between immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI plus TKI) regimens and dual immune checkpoint inhibitor (ICI plus ICI) combinations for treating metastatic renal cell carcinoma.
EP: 1.Evolving First-Line Treatment Strategies in Metastatic RCC: Key Factors Shaping Decision-Making
EP: 2.Translating Clinical Data Into the Practice Setting: Monotherapy and Combination Therapies in Intermediate/Poor-Risk mRCC
EP: 3.Navigating ICI Plus TKI Combinations for First-Line mRCC: Key Factors in Decision-Making
EP: 4.Key Disease Characteristics Influencing the Choice Between ICI + TKI and ICI + ICI Regimens in mRCC
- What specific disease characteristics most strongly influence your choice between immune checkpoint inhibitor plus tyrosine kinase inhibitor and immune checkpoint inhibitor plus immune checkpoint inhibitor regimens?
Promising Results from Phase 1/2 Trial of NKT2152 for Advanced Kidney Cancer
September 20th 2024NKT2152, a novel oral HIF-2α inhibitor, showed promising results in treating advanced clear cell renal cell carcinoma, with an objective response rate of 20% in all-comers and 26.3% in the dose-escalation population.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
